AG˹ٷ

STOCK TITAN

[Form 4] Quince Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quince Therapeutics (NASDAQ:QNCX) filed a Form 4 on June 28 2025 reporting that President Charles S. Ryan executed an insider purchase on June 18 2025.

Ryan bought 7,548 common shares at $1.20 each and simultaneously acquired 7,548 warrants with the same $1.20 exercise price, expiring 06/18/2030. His direct ownership rose to 130,009 common shares, an increase of roughly 5.8 %. No other material transactions or disclosures were included in the filing.

Quince Therapeutics (NASDAQ:QNCX) ha presentato un modulo Form 4 il 28 giugno 2025, segnalando che il Presidente Charles S. Ryan ha effettuato un acquisto interno il 18 giugno 2025.

Ryan ha acquistato 7.548 azioni ordinarie al prezzo di $1,20 ciascuna e ha contemporaneamente acquisito 7.548 warrant con lo stesso prezzo di esercizio di $1,20, con scadenza il 18/06/2030. La sua partecipazione diretta è salita a 130.009 azioni ordinarie, un aumento di circa il 5,8%. Nel deposito non sono state incluse altre transazioni o comunicazioni rilevanti.

Quince Therapeutics (NASDAQ:QNCX) presentó un Formulario 4 el 28 de junio de 2025 informando que el Presidente Charles S. Ryan realizó una compra interna el 18 de junio de 2025.

Ryan compró 7,548 acciones comunes a $1.20 cada una y simultáneamente adquirió 7,548 warrants con el mismo precio de ejercicio de $1.20, que vencen el 18/06/2030. Su propiedad directa aumentó a 130,009 acciones comunes, un incremento de aproximadamente el 5.8%. No se incluyeron otras transacciones o divulgaciones relevantes en la presentación.

Quince Therapeutics (NASDAQ:QNCX)� 2025� 6� 28� Form 4� 제출하여 사장 Charles S. Ryan� 2025� 6� 18� 내부� 매수� 실행했다� 보고했습니다.

ⲹ읶 7,548� 보통�� 주당 $1.20� 매수했으� 동시� 동일� 행사가� $1.20, 만기� 2030� 6� 18일인 7,548 워런�� 취득했습니다. 그의 직접 소유 주식 수는 � 5.8% 증가� 130,009� 보통�� 늘어났습니다. 제출서류에는 다른 중요� 거래� 공시� 포함되지 않았습니�.

Quince Therapeutics (NASDAQ:QNCX) a déposé un formulaire 4 le 28 juin 2025, indiquant que le président Charles S. Ryan a effectué un achat d’initié le 18 juin 2025.

Ryan a acheté 7 548 actions ordinaires au prix de 1,20 $ chacune et a simultanément acquis 7 548 bons de souscription avec le même prix d’exercice de 1,20 $, expirant le 18/06/2030. Sa détention directe est montée à 130 009 actions ordinaires, soit une augmentation d’environ 5,8 %. Aucun autre mouvement ou divulgation significative n’a été inclus dans le dépôt.

Quince Therapeutics (NASDAQ:QNCX) reichte am 28. Juni 2025 ein Formular 4 ein und berichtete, dass Präsident Charles S. Ryan am 18. Juni 2025 einen Insider-Kauf getätigt hat.

Ryan kaufte 7.548 Stammaktien zu je 1,20 $ und erwarb gleichzeitig 7.548 Warrants mit demselben Ausübungspreis von 1,20 $, die am 18.06.2030 verfallen. Sein Direktbesitz stieg auf 130.009 Stammaktien, eine Steigerung von etwa 5,8 %. Weitere wesentliche Transaktionen oder Offenlegungen wurden in der Einreichung nicht angegeben.

Positive
  • None.
Negative
  • None.

Quince Therapeutics (NASDAQ:QNCX) ha presentato un modulo Form 4 il 28 giugno 2025, segnalando che il Presidente Charles S. Ryan ha effettuato un acquisto interno il 18 giugno 2025.

Ryan ha acquistato 7.548 azioni ordinarie al prezzo di $1,20 ciascuna e ha contemporaneamente acquisito 7.548 warrant con lo stesso prezzo di esercizio di $1,20, con scadenza il 18/06/2030. La sua partecipazione diretta è salita a 130.009 azioni ordinarie, un aumento di circa il 5,8%. Nel deposito non sono state incluse altre transazioni o comunicazioni rilevanti.

Quince Therapeutics (NASDAQ:QNCX) presentó un Formulario 4 el 28 de junio de 2025 informando que el Presidente Charles S. Ryan realizó una compra interna el 18 de junio de 2025.

Ryan compró 7,548 acciones comunes a $1.20 cada una y simultáneamente adquirió 7,548 warrants con el mismo precio de ejercicio de $1.20, que vencen el 18/06/2030. Su propiedad directa aumentó a 130,009 acciones comunes, un incremento de aproximadamente el 5.8%. No se incluyeron otras transacciones o divulgaciones relevantes en la presentación.

Quince Therapeutics (NASDAQ:QNCX)� 2025� 6� 28� Form 4� 제출하여 사장 Charles S. Ryan� 2025� 6� 18� 내부� 매수� 실행했다� 보고했습니다.

ⲹ읶 7,548� 보통�� 주당 $1.20� 매수했으� 동시� 동일� 행사가� $1.20, 만기� 2030� 6� 18일인 7,548 워런�� 취득했습니다. 그의 직접 소유 주식 수는 � 5.8% 증가� 130,009� 보통�� 늘어났습니다. 제출서류에는 다른 중요� 거래� 공시� 포함되지 않았습니�.

Quince Therapeutics (NASDAQ:QNCX) a déposé un formulaire 4 le 28 juin 2025, indiquant que le président Charles S. Ryan a effectué un achat d’initié le 18 juin 2025.

Ryan a acheté 7 548 actions ordinaires au prix de 1,20 $ chacune et a simultanément acquis 7 548 bons de souscription avec le même prix d’exercice de 1,20 $, expirant le 18/06/2030. Sa détention directe est montée à 130 009 actions ordinaires, soit une augmentation d’environ 5,8 %. Aucun autre mouvement ou divulgation significative n’a été inclus dans le dépôt.

Quince Therapeutics (NASDAQ:QNCX) reichte am 28. Juni 2025 ein Formular 4 ein und berichtete, dass Präsident Charles S. Ryan am 18. Juni 2025 einen Insider-Kauf getätigt hat.

Ryan kaufte 7.548 Stammaktien zu je 1,20 $ und erwarb gleichzeitig 7.548 Warrants mit demselben Ausübungspreis von 1,20 $, die am 18.06.2030 verfallen. Sein Direktbesitz stieg auf 130.009 Stammaktien, eine Steigerung von etwa 5,8 %. Weitere wesentliche Transaktionen oder Offenlegungen wurden in der Einreichung nicht angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ryan Charles S.

(Last) (First) (Middle)
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD., SUITE 273

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/18/2025 A 7,548 A $1.2 130,009 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $1.2 06/18/2025 A 7,548 06/18/2025 06/18/2030 Common Shares 7,548 $0.125 7,548 D
Explanation of Responses:
/s/ Charles S. Ryan 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many QNCX shares did the president buy in the June 2025 Form 4 filing?

The filing shows President Charles S. Ryan acquired 7,548 common shares on 06/18/2025 at $1.20 per share.

What is Charles S. Ryan's total direct ownership after the transaction?

According to the Form 4, he now beneficially owns 130,009 common shares of Quince Therapeutics.

Did the insider acquire any derivative securities?

Yes. He obtained 7,548 warrants exercisable at $1.20 and expiring on 06/18/2030.
Quince

NASDAQ:QNCX

QNCX Rankings

QNCX Latest News

QNCX Latest SEC Filings

QNCX Stock Data

83.43M
39.50M
13.52%
23.46%
5.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO